The Senior Stack: Cognitive Resilience After 60

The standard nootropic stack designed for healthy young adults doesn't translate cleanly to older users. The metabolic, cardiovascular, and neurological context changes; the dose-response curves shift; the priority outcomes change from acute enhancement to long-term healthspan. The stack for users over 60 is meaningfully different in composition and emphasis.

This is not because aging users need weaker compounds. Several of the most evidence-based interventions for cognitive function in aging are actually higher-dose and more aggressive than the enhancement protocols for younger users. The composition is different because the bottlenecks are different.

The aging biology context

NAD+ levels decline 40-50% between age 20 and 60. Mitochondrial function declines steadily through middle age. Sleep architecture changes, slow-wave sleep duration drops by 50% or more between young adulthood and age 60. Insulin sensitivity declines. Inflammation increases. Cholinergic neuron populations slowly decrease.

Each of these changes opens specific intervention opportunities. The senior stack addresses each rather than trying to push focus and energy harder.

The cardiovascular floor

Cardiovascular health drives cognitive health. The brain consumes 20% of resting metabolic output; vascular compromise produces silent cognitive decline that accumulates. Most aging-cognitive-decline trajectories have substantial vascular components.

Omega-3 (DHA/EPA combination) 2000-3000 mg/day. The cardiovascular evidence is substantial; the cognitive decline reduction signal (Morris 2003) is real.

CoQ10 ubiquinol 100-200 mg/day with fat. Particularly important for users on statins, where the statin pathway suppresses endogenous CoQ10 synthesis. Banach 2015 meta-analysis demonstrates myalgia benefit; the cardiovascular Q-SYMBIO trial supports use in heart failure.

Vitamin K2 (MK-7) 100-180 mcg/day with fat. Directs calcium away from arterial walls toward bones. Knapen 2015 demonstrated arterial stiffness improvement. Pair with vitamin D3.

Vitamin D3 2000-5000 IU/day with fat. Maintain blood 25-OH-D at 40-60 ng/ml. Deficiency in seniors is common and contributes to cognitive decline, falls, and cardiovascular risk.

Magnesium glycinate 300-400 mg elemental at bedtime. Magnesium deficiency is common in older adults; repletion supports cardiovascular function and sleep.

These are the floor. Cognitive support on a poor cardiovascular base produces minimal benefit.

The mitochondrial layer

Mitochondrial function declines with age. Several compounds support mitochondrial biogenesis and function.

CoQ10 (already in cardiovascular floor) supports mitochondrial electron transport.

NAD+ precursors, NR or NMN 500 mg/day morning. The biomarker improvement is well-replicated; the clinical benefit in healthy older adults is emerging.

PQQ 20 mg/day stimulates mitochondrial biogenesis via PGC-1α. The Itoh 2016 evidence for cognitive function in elderly adults supports this.

Acetyl-L-carnitine 1000-2000 mg/day in the morning. Malaguarnera 2008 demonstrated fatigue reduction in elderly users; mitochondrial function support is the proposed mechanism.

Alpha-lipoic acid 300-600 mg/day. The Ames laboratory popularised the ALCAR + ALA pairing for mitochondrial support.

For users over 60, the mitochondrial stack is one of the highest-value interventions. The evidence is stronger here than for many enhancement-focused compounds in younger users.

The cognitive resilience layer

Cholinergic support takes priority in aging users because cholinergic neuron populations decline.

CDP-choline (citicoline) 500 mg/day. The Alzheimer's evidence (Davalos 2002 ICTUS trial) and the McGlade 2012 cognitive function evidence support use.

Bacopa monnieri 300 mg/day, indefinitely. The Stough trials extended to older populations with comparable benefits. The 8-12 week timeline still applies.

Phosphatidylserine 100 mg/day. The Crook 1991 age-related memory impairment evidence is foundational; subsequent trials replicate.

Lion's Mane dual extract 1000-2000 mg/day. The Mori 2009 mild cognitive impairment evidence is particularly relevant here.

Huperzine A 100-200 mcg/day, cycled (two weeks on, two off). The Wang 2009 Cochrane evidence in Alzheimer's; smaller signal in cognitively healthy seniors.

This stack overlaps with the standard memory stack but the priority is higher and the dosing is closer to the upper end of the clinical ranges.

The sleep architecture layer

Aging sleep architecture degrades substantially, slow-wave sleep drops 50% between 30 and 70, REM is fragmented, total sleep time declines. The decline accelerates cognitive decline through reduced consolidation.

Magnesium L-threonate 1500 mg one hour before bed (in addition to magnesium glycinate). The Liu 2016 trial demonstrated cognitive benefit at this dose specifically in older adults.

Low-dose melatonin 0.3-0.5 mg if sleep onset is impaired. Higher doses are unnecessarily strong and produce morning grogginess.

Glycine 3 g before bed if maintaining sleep through the night is the issue.

L-theanine 200 mg before bed if racing thoughts are an issue.

Apigenin 50 mg before bed if difficulty falling asleep is the issue.

Sleep is the single most important intervention. Compounds support it; they don't substitute for sleep hygiene and consistent timing.

The blood sugar layer

Insulin resistance and prediabetes accelerate cognitive decline. The Alzheimer's-as-type-3-diabetes hypothesis has substantial mechanistic support.

Berberine 500 mg twice daily with meals. The DPP-quality evidence for glucose regulation; comparable to metformin in some trials.

Alpha-lipoic acid (already in mitochondrial layer) supports insulin sensitivity.

Cinnamon extract may have modest blood glucose effects but the evidence is weak.

For users with diagnosed prediabetes or type 2 diabetes, metformin 500-1000 mg twice daily under prescription is the strongest evidence-based intervention. Off-label metformin for longevity in non-diabetic users is increasingly common but the evidence base is smaller.

What to skip

High-stimulant protocols. The 400 mg caffeine routine that worked at 30 produces anxiety, hypertension, and sleep disruption at 65. Reduce to 100-150 mg morning maximum.

Aggressive racetam stacks. Piracetam at 1600 mg/day is reasonable; pushing the cholinergic load with multiple racetams plus huperzine plus Alpha-GPC produces over-cholinergic symptoms in older users.

Modafinil daily. The cardiovascular load is meaningful in older users; intermittent use only and only with appropriate prescription oversight.

Yohimbine. The cardiovascular risk and CYP2D6 variability make this inappropriate for most older users.

Phenibut, kava, kratom. Higher hepatotoxicity risk with concurrent medications common in older users.

The interaction question

Older users typically take 3-7 prescription medications. Each adds interaction risk with supplements. The simple rule: list every supplement on every doctor visit; ask the pharmacist about specific interactions before starting any new supplement.

Common interactions to watch: omega-3 and warfarin (additive bleeding risk); CoQ10 and warfarin (variable effect on INR); magnesium and bisphosphonates (absorption interference); vitamin K and warfarin (direct opposition); berberine and metformin (additive hypoglycaemia risk).

The honest priorities

For users over 60 trying to optimise cognitive healthspan, the order of priority is roughly:

1. Cardiovascular floor (omega-3, CoQ10, K2, D3, magnesium) 2. Sleep optimisation (magnesium L-threonate, sleep hygiene) 3. Exercise (aerobic + resistance, the largest single intervention) 4. Mitochondrial support (NAD+ precursors, PQQ, ALCAR) 5. Cognitive support (Bacopa, CDP-choline, Lion's Mane) 6. Stress management (Ashwagandha if dysregulated) 7. Acute enhancement (caffeine + theanine, modest)

Most users want to start with the acute enhancement because the effect is immediate. The priority for aging users is reversed, the floor matters more than the ceiling. Building from the bottom up produces durable cognitive function across decades. Building from the top down produces short-term enhancement on a degrading foundation.